A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines

Advanced Drug Delivery Reviews

Volumn 64, Issue 15, 2012, Pages 1706-1716

  Szebeni, János ^a,d,e   Bedocs, Péter ^a,b   Csukás, Domokos ^a   Rosivall, László ^a,f   Bünger, Rolf ^b   Urbanics, Rudolf ^a,c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c SeroScience Ltd   (Hungary)

^d BAY ZOLTÁN NONPROFIT LTD FOR APPLIED RESEARCH   (Hungary)

^e UNIVERSITY OF MISKOLC   (Hungary)

^f INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

(Pseudo)allergy; Adverse drug effects; Anaphylactic shock; Animal models; Circulation; Immune toxicity; Nanomedicines; PIM cells

Indexed keywords

ANAPHYLACTIC SHOCK; ANAPHYLATOXIN; ANIMAL MODEL; DRUG CARRIER; DRUG EFFECTS; HYPERSENSITIVITY REACTION; INTRAVASCULAR; INTRAVENOUS ADMINISTRATION; LIPOSOMAL DOXORUBICIN; MOLECULAR PATTERNS; NANO PARTICULATES; NANOMEDICINES; NEW THEORY; PORCINE MODELS; REPRODUCIBILITIES; SURFACE RECEPTORS; TACHYPHYLAXIS; UNDERLYING MECHANISM; UNIQUE FEATURES;

ALLERGIES; BOILER CIRCULATION; LIPOSOMES;

DRUG INFUSION;

AMPHOTERICIN B; DOXORUBICIN; DRUG CARRIER; LIPOSOME; NANOCARRIER; NANOPARTICLE; POLYETHYLENEIMINE; POLYMER; THROMBOXANE A2;

ADVERSE OUTCOME; ALLERGY; BLOOD CELL; CELL FUNCTION; CELLULAR DISTRIBUTION; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CLINICAL FEATURE; COMPLEMENT ACTIVATION; COMPLEMENT ACTIVATION RELATED PSEUDOALLERGY; CONCENTRATION (PARAMETERS); DESENSITIZATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; EXPERIMENTAL PIG; FLUSHING; HUMAN; IN VIVO STUDY; INFUSION RATE; LUNG ALVEOLUS MACROPHAGE; MOLECULAR PATHOLOGY; NANOMEDICINE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RASH; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SKIN ALLERGY; TACHYPHYLAXIS;

ANIMALS; COMPLEMENT ACTIVATION; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG HYPERSENSITIVITY; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; NANOPARTICLES; POLYMERS; REPRODUCIBILITY OF RESULTS; SPECIES SPECIFICITY; SWINE;

EID: 84869152246     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.07.005     Document Type: Review

References (68)

1. Szebeni J., Moghimi S.M. Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions. J. Liposome Res. 2009, 19:85-90.
2. Szebeni J., Muggia F., Gabizon G., Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv. Drug Deliv. Rev. 2011, 63:1020-1030.
3. Szebeni J., Baranyi B., Savay S., Milosevits J., Bodo M., Bunger D.S.R., Alving C.R. The interaction of liposomes with the complement system: in vitro and in vivo assays. Methods Enzymol. 2003, 373:136-154.
4. Szebeni J., Barenholz Y. Complement activation, immunogenicity, and immune suppression as potential side effects of liposomes. Handbook of Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications 2012, 309-334. Pan Stanford Publishing Pte. Ltd., Singapore. D. Peer (Ed.).
5. Szebeni J. Hemocompatibility testing for nanomedicines and biologicals: predictive assays for complement mediated infusion reactions. Eur. J. Nanomed. 2012, 5:33-53.
6. Wassef N.M., Johnson S.H., Graeber G.M., Swartz G.M., Schultz C.L., Hailey J.R., Johnson A.J., Taylor D.G., Ridgway R.L., Alving C.R. Anaphylactoid reactions mediated by autoantibodies to cholesterol in miniature pigs. J. Immunol. 1989, 143:2990-2995.
7. Szebeni J., Fontana J.L., Wassef N.M., Mongan P.D., Morse D.S., Dobbins D.E., Stahl G.L., Bünger R., Alving C.R. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudo-allergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 1999, 99:2302-2309.
8. Szebeni J., Baranyi B., Savay S., Bodo M., Morse D.S., Basta M., Stahl G.L., Bunger R., Alving C.R. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am. J. Physiol. 2000, 279:H1319-H1328.
9. Szebeni J., Baranyi L., Sávay S., Bodó M., Milosevits J., Alving C.R., Bünger R. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am. J. Physiol. 2006, 290:H1050-H1058.
10. Szebeni J., Bedocs P., Rozsnyay Z., Weiszhár Z., Urbanics R., Rosivall L., Cohen R., Garbuzenko O., Báthori G., Tóth M., Bünger R., Barenholz Y. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. Nanomedicine NBM 2012, 8:176-184.
11. Szebeni J., Bedocs P., Urbanics R., Bunger R., Rosivall L., Tóth M., Barenholz Y. Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model. J. Control. Release 2012, 160:382-387.
12. Gabizon A., Isacson R., Libson E., Kaufman B., Uziely B., Catane R., Ben-Dor C.G., Rabello E., Cass Y., Peretz T., et al. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol. 1994, 33:779-786.
13. Uziely B., Jeffers S., Muggia F. Low doses of dexamethasone protect against paclitaxel (Taxol)-related hypersensitivity reactions following cycle 1 [letter]. Ann. Oncol. 1994, 5:474.
14. Uziely B., Jeffers S., Isacson R., Kutsch K., Wei-Tsao D., Yehoshua Z., Libson E., Muggia F.M., Gabizon A. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol. 1995, 13:1777-1785.
15. de Marie S. Liposomal and lipid-based formulations of amphotericin B. Leukemia 1996, 10(Suppl. 2):S93-S96.
16. Muggia F.M., Hainsworth J.D., Jeffers S., Miller P., Groshen S., Tan M., Roman L., Uziely B., Muderspach L., Garcia A., Burnett A., Greco F.A., Morrow C.P., Paradiso L.J., Liang L.J. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 1997, 15:987-993.
17. Northfelt D.W., Dezube B.J., Thommes J.A., Levine R., Von Roenn J.H., Dosik G.M., Rios A., Krown S.E., Du Mond C., Mamelok R.D. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J. Clin. Oncol. 1997, 15:653-659.
18. Northfelt D.W., Dezube B.J., Thommes J.A., Miller B.J., Fischl M.A., Friedman-Kien A., Kaplan L.D., Du Mond C., Mamelok R.D., Henry D.H. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J. Clin. Oncol. 1998, 16:2445-2451.
19. Gabizon A.A., Muggia F.M. Initial clinical evaluation of pegylated liposomal doxorubicin in solid tumors. Long-Circulating Liposomes: Old Drugs, New Therapeutics 1998, 155-174. Landes Bioscience, Austin, TX. M.C. Woodle, G.S. (Eds.).
20. Koukourakis M.I., Koukouraki S., Giatromanolaki A., Archimandritis S.C., Skarlatos J., Beroukas K., Bizakis J.G., Retalis G., Karkavitsas N., Helidonis E. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J. Clin. Oncol. 1999, 17:3512-3521.
21. Lyass O., Uziely B., Ben-Yosef R., Tzemach D., Heshing N.I., Lotem M., Brufman G., Gabizon A.A. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000, 89:1037-1047.
22. Gordon A.N., Granai C.O., Rose P.G., Hainsworth J., Lopez A., Weissman C., Rosales R., Sharpington T. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J. Clin. Oncol. 2000, 18:3093-3100.
23. Hubert A., Lyass O., Pode D., Gabizon A. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs 2000, 11:123-127.
24. Lyass O., Hubert A., Gabizon A.A. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies. Clin. Cancer Res. 2001, 7:3040-3046.
25. Kinsky S.C., Haxby J.A., Zopf D.A., Alving C.R., Kinsky C.B. Complement-dependent damage to liposomes prepared from pure lipids and Forssman hapten. Biochemistry 1969, 8:4149-4158.
26. Alving C.R., Kinsky S.C., Haxby J.A., Kinsky C.B. Antibody binding and complement fixation by a liposomal model membrane. Biochemistry 1969, 8:1582-1587.
27. Szebeni J. The interaction of liposomes with the complement system. Crit. Rev. Ther. Drug Carrier Syst. 1998, 15:57-88.
28. Hugli T.E., Chenoweth D.E. Biologically active peptides of complement. Techniques and significance of C3a and C5a measurements. Laboratory and Research Methods in Biology and Medicine 1980, 443. Alan R. Liss, New York. R.M. Nakamura, W.R. Dito, E.S. Tucher (Eds.).
29. Hugli T.E., Morgan E.L. Mechanisms of leukocyte regulation by complement-derived factors. Contemp. Top. Immunobiol. 1984, 14:109-153.
30. Hugli T.E. Structure and function of anaphylatoxins. Springer Semin. Immunopathol. 1984, 7:193-219.
31. Marceau F., Lundberg C., Hugli T.E. Effects of anaphylatoxins on circulation. Immunopharmacology 1987, 14:67-84.
32. Szebeni J., Muggia F.M., Alving C.R. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J. Natl. Cancer Inst. 1998, 90:300-306.
33. Szebeni J., Alving C.R., Savay S., Barenholz Y., Priev A., Danino D., Talmon Y. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Intern. Immunopharm. 2001, 1:721-735.
34. Weiszhár Z., Czúcz J., Révész C., Rosivall L., Szebeni J., Rozsnyay Z. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur. J. Pharm. Pharmaceutics 2012, 45:492-498.
35. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced immune toxicity. Toxicology 2005, 216:106-121.
36. Johansson S.G.O., Bieber T., Dahl R., Friedmann P.S., Lanier B.Q., Lockey R.F., Motala C., Ortega Martell J.A., Platts-Mills T., Ring J., Thien F.P.V.C., Williams H.C. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization. J. Allergy Clin. Immunol 2003, 113:832-836.
37. Biological evaluation of medical devices - part 4: selection of tests for interaction with blood. ANSI/AAMI/ISO 10993-4:2002/(R) 10 March 2009 2009.
38. Chanan-Khan A., Szebeni J., Savay S., Liebes L., Rafique N.M., Alving C.R., Muggia F.M. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann. Oncol. 2003, 14:1430-1437.
39. Szebeni J., Bunger R., Baranyi L., Bedocs P., Toth M., Rosivall L., Barenholz Y., Alving C.R. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. J. Liposome Res. 2007, 17:107-117.
40. Merkel O., Urbanics R., Bedocs P., Rozsnyay Z., Rosivall L., Toth M., Kissel T., Szebeni J. In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine-graft-poly(ethylene glycol) block copolymers. Biomaterials 2011, 32:4936-4942.
41. Szebeni J., Milosevits J., Bunger R., Laverman P., Metselaar J.M., Storm G., Chanan-Khan A., Liebes L., Muggia F.M., Cohen R., Barenholz Y., Alving C.R. Role of complement activation in hypersensitivity reactions to Doxil and HYNIC-PEG liposomes: experimental and clinical studies. J. Liposome Res. 2002, 12:165-172.
42. Szebeni J. Complement activation-related pseudoallergy: mechanism of anaphylactoid reactions to drug carriers and radiocontrast agents. The Complement System: Novel Roles in Health and Disease 2004, 399-440. Kluwer, Boston. J. Szebeni (Ed.).
43. Szebeni J. Hypersensitivity reactions to radiocontrast media: the role of complement activation. Curr. Allergy Asthma Rep. 2004, 4:25-30.
44. Weil M.H., Bisera J., Trevino R.P., Rackow E.C. Cardiac output and end-tidal carbon dioxide. Crit. Care Med. 1985, 13:907-909.
45. Richter A.W., Kerblom E. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int. Arch. Allergy Appl. Immunol. 1984, 74:36-39.
46. Armstrong J.K., Hempel G., Koling S., Chan L.S., Fisher T., Meiselman H.J., Garratty G. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007, 110:103.
47. Ishida T., Ichihara M., Wang X., Yamamoto K., Kimura J., Majima E., Kiwada H. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control. Release 2006, 112:15-25.
48. Ishihara T., Takeda M., Sakamoto H., Kimoto A., Kobayashi C., Takasaki N., Yuki K., Tanaka K., Takenaga M., Igarashi R., Maeda T., Yamakawa N., Okamoto Y., Otsuka M., Ishida T., Kiwada H., Mizushima Y., Mizushima T. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm. Res. 2009, 10:2270-2279.
49. Koide H., Asai T., Hatanaka K., Akai S., Ishii T., Kenjo E., Ishida T., Kiwada H., Tsukada H., Oku N. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. Int. J. Pharm. 2010, 392:218-223.
50. Ishida T., Masuda K., Ichikawa T., Ichihara M., Irimura K., Kiwada H. Accelerated clearance of a second injection of PEGylated liposomes in mice. Int. J. Pharm. 2003, 255:167-174.
51. Ishida T., Maeda R., Ichihara M., Irimura K., Kiwada H. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J. Control. Release 2003, 35-42.
52. Milosevits G., Rozsnyay Z., Kozma G.T., Milosevits J., Tömöry G., Robotka H., Rosivall L., Szebeni J. Flow cytometric analysis of supravesicular structures in doxorubicin-containing pegylated liposomes. Chem. Phys. Lipids 2012, 165:482-487.
53. Hamad I., Hunter A.C., Szebeni J., Moghimi S.M. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol. Immunol. 2008, 46:225-232.
54. Andersen A.J., Hashemi1 S.H., Andresen T.L., Hunter A.C., Moein Moghimi S.M.S. Complement: alive and kicking nanomedicines. J. Biomed. Nanotechnol. 2009, 5:364-372.
55. Ohnishi H., Oka K., Mizuno S., Nakamura T. Identification of mannose receptor as receptor for hepatocyte growth factor β-chain: novel ligand-receptor pathway for enhancing macrophage phagocytosis. J. Biol. Chem. 2012, 287:13371-13381.
56. Sorvillo N., Pos W., van den Berg L.M., Fijnheer R., Martinez-Pomares L., Geijtenbeek T.B., Herczenik E., Voorberg J. The macrophage mannose receptor promotes uptake of ADAMTS13 by dendritic cells. Blood 2012, 119:3828-3835.
57. Winkler G.C. Pulmonary intravascular macrophages in domestic animal species: review of structural and functional properties. Am. J. Anat. 1988, 181:217-234.
58. Brain J.D., Molina R.M., DeCamp M.M., Warner A.E. Pulmonary intravascular macrophages: their contribution to the mononuclear phagocyte system in 13 species. Am. J. Physiol. Lung Cell. Mol. Physiol. 1999, 276:146-154.
59. Atwal O.S., Minhas K.J. In vivo interaction of cationised ferritin with the surface coat and endocytosis by pulmonary intravascular macrophages: a tracer kinetic study. J. Anat. 1992, 181:313-325.
60. Longworth K.E. The comparative biology of pulmonary intravascular macrophages. Front. Biosci. 1997, 2:232-241.
61. Carrasco L., Ruiz-Villamor E., Gómez-Villamandos J.C., Salguero F.J., Bautista M.J., Maciá M., Quezada M., Jover A. Classical swine fever: morphological and morphometrical study of pulmonary intravascular macrophages. J. Comp. Path. 2001, 125:1-7.
62. Aharonson-Raz K., Singh B. Pulmonary intravascular macrophages and endotoxin-induced pulmonary pathophysiology in horses. Can. J. Vet. Res. 2010, 74:45-49.
63. Brain J.D. Mechanisms, measurement, and significance of lung macrophage function. Environ. Health Perspect. 1992, 97:5-10.
64. Atwal O.S., Williams C.S., Minhas K.J., Nijjar M.S. In situ heparin-induced peroxisomal reticulum and biogenesis of peroxisomes in pulmonary intravascular macrophages (PIMs) of caprine lung: an ultrastructural and cytochemical study. Anat. Rec. 2002, 266:69-80.
65. Schneberger D., Aharonson-Raz K., Singh B. Pulmonary intravascular macrophages and lung health: what are we missing?. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 302:498-503.
66. Morton D., Bertram T.A. Isolation and preliminary in vitro characterization of the porcine pulmonary intravascular macrophage. J. Leukoc. Biol. 1988, 43:403-410.
67. Wassef A., Janardhan K., Pearce J.W., Singh B. Toll-like receptor 4 in normal and inflamed lungs and other organs of pig, dog and cattle. Histol. Histopathol. 2004, 19:1201-1208.
68. Schneberger D., Lewis D., Caldwell S., Singh B. Expression of toll-like receptor 9 in lungs of pigs, dogs and cattle. Int. J. Exp. Pathol. 2011, 92:1-7.